Trimethoprim/sulfamethoxazole-induced phenytoin toxicity in the elderly: A population-based study

British Journal of Clinical Pharmacology

Volumn 71, Issue 4, 2011, Pages 544-549

  Antoniou, Tony ^a,b   Gomes, Tara ^a,c   Mamdani, Muhammad M ^a,c,d,e   Juurlink, David N ^a,c,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f Sunnybrook Health Sciences Centre   (Canada)

Author keywords

Drug interaction; Nested case control; Patient safety; Pharmacoepidemiology; Phenytoin; Population based; Trimethoprim sulfamethoxazole

Indexed keywords

AMOXICILLIN; COTRIMOXAZOLE; PHENYTOIN;

AGE DISTRIBUTION; AGED; AGING; ARTICLE; CANADA; CONTROLLED STUDY; DRUG INTOXICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTICONVULSANTS; CASE-CONTROL STUDIES; DRUG INTERACTIONS; HUMANS; MALE; PHENYTOIN; REGRESSION ANALYSIS; RISK FACTORS; TIME FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 79952614248     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03866.x     Document Type: Article

References (21)

1. Pugh MJ, Van Cott AC, Cramer JA, Knoefel JE, Amuan ME, Tabares J, Ramsay RE, Berlowitz DR; Treatment In Geriatric Epilepsy Research (TIGER) Team. Trends in antiepileptic drug prescribing for older patients with new-onset epilepsy: 2000-2004. Neurology 2008; 70: 2171-8.
2. Garrard J, Harms S, Hardie N, Eberly LE, Nitz N, Bland P, Gross CR, Leppik IE. Antiepileptic drug use in nursing home admissions. Ann Neurol 2003; 54: 75-85.
3. Bach B, Hansen JM, Kampmann JP, Rasmussen SN, Skovsted L. Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet 1981; 6: 389-96.
4. Bauer LA, Blouin RA. Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther 1982; 31: 301-4.
5. Battino D, Croci D, Mamoli D, Messina S, Perucca E. Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. Epilepsy Res 2004; 59: 155-65.
6. Morrell MJ. Antiepileptic medications for the treatment of epilepsy. Semin Neurol 2002; 22: 247-58.
7. Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit 2004; 25: 534-40.
8. Osorio I, Burnstine TH, Remler B, Manon-Espaillat R, Reed RC. Phenytoin-induced seizures: a paradoxical effect at toxic concentrations in epileptic patients. Epilepsia 1989; 30: 230-4.
9. Wen X, Wang JS, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 2002; 30: 631-5.
10. Doecke CJ, Veronese ME, Pond SM, Miners JO, Birkett DJ, Sansom LN, McManus ME. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 1991; 31: 125-30.
11. Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996; 24: 1401-3.
12. Hansen JM, Kampmann JP, Siersbaek-Nielsen K, Lumholtz IB, Arrøe M, Abildgaard U, Skovsted L. The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand Suppl 1979; 624: 106-10.
13. Gillman MA, Sandyk R. Phenytoin toxicity and co-trimoxazole. Ann Intern Med 1985; 102: 559.
14. Wilcox JB. Phenytoin intoxication and cotrimoxazole. N Z Med J 1981; 94: 235-6.
15. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289: 1652-8.
16. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-51.
17. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354: 1352-61.
18. Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298: 2634-43.
19. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics 1984; 40: 63-75.
20. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007; 26: 734-53.
21. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 854-64.